21 related articles for article (PubMed ID: 8255163)
1. Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.
Sasayama S
Drug Saf; 2004; 27 Suppl 1():19-24. PubMed ID: 15293850
[TBL] [Abstract][Full Text] [Related]
2. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Sato Y; Matsumori A; Sasayama S
J Mol Cell Cardiol; 1995 Oct; 27(10):2265-73. PubMed ID: 8576941
[TBL] [Abstract][Full Text] [Related]
3. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
[TBL] [Abstract][Full Text] [Related]
4. The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Jiang H; Bielekova B; Okazaki H; Clarence-Smith K; Johnson KP; Bergey G; Martin R; Dhib-Jalbut S
J Neuroimmunol; 1999 Jun; 97(1-2):134-45. PubMed ID: 10408967
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
6. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation: a new horizon for medical treatment of heart failure.
Sasayama S; Matsumori A; Matoba Y; Matsui S; Yamada T; Shioi T; Sato Y; Doyama K; Kishimoto C
J Card Fail; 1996 Dec; 2(4 Suppl):S287-94. PubMed ID: 8951591
[TBL] [Abstract][Full Text] [Related]
8. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Furusawa S; Ohashi Y; Asanoi H
J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line.
Shioi T; Matsumori A; Matsui S; Sasayama S
Life Sci; 1994; 54(1):PL11-6. PubMed ID: 8255163
[TBL] [Abstract][Full Text] [Related]
10. Vesnarinone: a potential cytokine inhibitor.
Sasayama S; Matsumori A
J Card Fail; 1996 Sep; 2(3):251-8. PubMed ID: 8891863
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
